What Sunosi Treats: Main Uses and Benefits

The medication is commonly used in adult patients to address the symptoms that interfere with daily functioning, specifically Excessive Daytime Sleepiness (EDS), a core symptom of two chronic conditions. The therapeutic scope includes EDS associated with Narcolepsy and EDS associated with Obstructive Sleep Apnea (OSA) when symptoms persist despite primary management of the underlying breathing disorder.

Solriamfetol is generally applied in clinical settings where supportive symptom management is appropriate, particularly when the pathological tendency to sleep during major waking periods creates noticeable physiological strain. It provides supportive relief by helping to reduce this pathological tendency, which may assist with improving sustained wakefulness and alertness throughout the day.

This focus on functional relief is summarized by the statement: “The treatment supports the patient during difficult episodes by easing distress and contributing to improved comfort during symptomatic periods.” By helping to ease this symptom burden, the medication can support maintaining functional stability, which is relevant for the patient's overall health-related quality of life.

---

Quick Fact: Management of Excessive Daytime Sleepiness (EDS)

Property	Description
Target Symptom	Chronic Excessive Daytime Sleepiness (EDS)
Primary Contexts	Narcolepsy and Residual OSA Sleepiness
Core Benefit	May assist with sustained wakefulness and alertness
Usage Role	Symptomatic management / Supportive therapy

Regulatory References

1. European Medicines Agency overview

This medicine is approved for use only in adults (18 years of age and older). Safety and effectiveness have not been established in pediatric patients.

Contraindicated Populations

The medicine must not be used in patients who:

• Are currently taking or have taken a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days, due to the risk of a hypertensive reaction.
• Have uncontrolled hypertension or a history of serious cardiac problems such as a heart attack in the past year, unstable angina, or serious heart arrhythmias (as per EU/UK regulation).

Use Restrictions and Special Considerations

Use is restricted or requires caution in several groups:

• Renal Impairment: Patients with moderate to severe kidney impairment require a specific dosage adjustment; use is not recommended in those with End-Stage Renal Disease (ESRD).
• Cardiovascular History: Caution is advised for patients with known cardiovascular or cerebrovascular disease; blood pressure must be assessed and controlled before and during treatment.
• Psychiatric History: Caution is necessary in patients with a history of psychosis or bipolar disorders.
• Obstructive Sleep Apnea (OSA): For OSA patients, the underlying airway obstruction must be treated (e.g., with CPAP) for at least one month before starting this medicine.

Pregnancy and Lactation

• Pregnancy: The medicine is not recommended during pregnancy, and women of childbearing potential are advised to use effective contraception (EU/UK). A Pregnancy Registry is established to monitor outcomes.
• Breastfeeding: The medicine is excreted in human milk, and use is not recommended due to the inability to exclude a risk to the nursing infant.

Contraindicated Combinations and Timing Rules

The medicine is formally contraindicated with Monoamine Oxidase Inhibitors (MAOIs). This combination is strictly prohibited due to the risk of a severe hypertensive reaction (hypertensive crisis) resulting from increased adrenergic effects. Co-administration must be avoided, and a 14-day separation period is required following the discontinuation of any MAOI treatment before starting Solriamfetol.

Pharmacodynamic and Pharmacokinetic Status

Caution is required when co-administering drugs that may increase blood pressure and/or heart rate (such as sympathomimetics), as this may lead to additive effects. Similarly, caution is advised for co-administration with other dopaminergic drugs due to the potential for pharmacodynamic interactions. Regulatory documents note these specific combinations have not been formally evaluated.

Based on official assessments, clinically significant pharmacokinetic interactions are not expected with major Cytochrome P450 (CYP) enzymes or transporters. The extent of drug exposure (AUC/Cmax) is also not altered by consumption of a high-fat, high-calorie meal.

Population-Specific Exposure Changes

For patients with moderate or severe renal impairment, the drug’s reduced clearance results in a prolonged half-life and significantly increased systemic exposure. This change in pharmacokinetics elevates the risk of cardiovascular adverse events and psychiatric symptoms. Therefore, use is not recommended for patients with End-Stage Renal Disease (ESRD).

Selective Inhibition of Dual Reuptake

Solriamfetol is classified as a selective dopamine and norepinephrine reuptake inhibitor (DNRI). Its action centers on binding to the Dopamine Transporter ( DAT) and the Norepinephrine Transporter ( NET) in the central nervous system. This molecular interaction physically blocks the recycling process, thereby sustaining higher concentrations of these two neurotransmitters associated with central arousal in the synaptic space. This mechanism results in sustained potentiation of central signaling, rather than forced, immediate release.

Focused Central Arousal Pathway Modulation

The resulting elevation in extracellular dopamine and norepinephrine amplifies the activity of the ascending monoaminergic pathways that regulate the brain’s arousal state. By augmenting the output of these specific brain circuits, Solriamfetol enhances the output of central arousal circuits. Importantly, the compound exhibits minimal activity on other major sleep-regulating systems, such as the orexin or histamine pathways, reflecting its selective action on the catecholamine systems.

How to use Sunosi: Official Administration Guidelines

Sunosi (solriamfetol) is an oral tablet taken once daily upon awakening to improve wakefulness. It may be taken with or without food. Due to its stimulating effects, administration should be avoided within 9 hours of planned bedtime to prevent interference with sleep.

Dosing and Titration

For adults with narcolepsy, the initial dose is 75 mg once daily. For adults with obstructive sleep apnea (OSA), the initial dose is 37.5 mg once daily.

Condition	Initial Daily Dose	Maximum Daily Dose
Narcolepsy	75 mg	150 mg
Obstructive Sleep Apnea (OSA)	37.5 mg	150 mg

Dosage may be doubled at intervals of at least 3 days based on efficacy and tolerability, up to a maximum recommended dose of 150 mg once daily. The 75 mg tablet is functionally scored and can be split in half to achieve the 37.5 mg starting dose.

Special Use Conditions

• Missed Dose: If a dose is missed, take it as soon as possible, provided there are at least 9 hours until planned bedtime. If closer than 9 hours to bedtime, skip the missed dose and take the next dose at the regular time the next day. Do not double doses.
• Renal Impairment: Dose adjustments are mandatory for moderate (maximum 75 mg) and severe (maximum 37.5 mg) renal impairment.
• Obstructive Sleep Apnea (OSA): Treatment for the underlying airway obstruction (e.g., Continuous Positive Airway Pressure/CPAP) must be continued during treatment with Sunosi and must have been used for at least one month prior to initiation.

Research evidence / Overview of studies for Sunosi

---

Evidence from Clinical Trials for Narcolepsy

Research into Sunosi for excessive daytime sleepiness (EDS) associated with Narcolepsy has been conducted primarily through short-term, randomized, double-blind, placebo-controlled trials typically lasting about 12 weeks. The main outcomes research examined included an objective measure of wakefulness, specifically the mean sleep latency (time until falling asleep) during the Maintenance of Wakefulness Test (MWT), and the Epworth Sleepiness Scale (ESS), which assesses a patient's self-reported feelings of sleepiness.

Studies reported measurements that described how symptoms evolved in the observed populations, noting patterns in both the objective MWT scores and the subjective ESS scores when comparing groups who were studied with the medicine versus those studied with an inactive placebo. These research findings described changes measured during the study period related to wakefulness. Comparative evidence is lacking; the core research does not include direct, head-to-head trials against other prescribed wake-promoting agents used for narcolepsy.

---

Evidence from Clinical Trials for Obstructive Sleep Apnea (OSA)

For the management of excessive daytime sleepiness (EDS) that persists in adult patients with Obstructive Sleep Apnea (OSA), research utilized similar study designs. These trials focused specifically on the EDS component, including patient populations both adherent and non-adherent to other primary OSA treatment, such as Continuous Positive Airway Pressure (CPAP). The research monitored changes in the same core outcomes: the MWT objective wakefulness test and the ESS subjective sleepiness scale.

Analyses described patterns in the observed measurements across the different study groups compared to placebo. However, the research does not determine whether the medicine affects the underlying airway obstruction of OSA itself; the trials were not designed to address the core disease pathology of the breathing disorder. The data show patterns related to the symptom of sleepiness, not the cause of OSA.

---

The Role of Long-Term Studies and What Remains Uncertain

The main evidence for the sustained maintenance of the studied measurements comes from open-label extension (OLE) studies, which followed patients for up to one year after the initial controlled phase. Because OLE studies do not include a simultaneous placebo group, the degree of certainty about the findings is lower than that from the initial controlled trials. This means there is limited information for long-term outcomes from the most rigorous type of research. Data for certain groups remain insufficient, such as for pediatric patients or women who are pregnant or breastfeeding; consequently, results apply only to the populations studied.

Common questions about Sunosi (FAQ)

Q: Is Sunosi a type of stimulant like Adderall or Ritalin?

Official documents describe solriamfetol as a selective dopamine and norepinephrine reuptake inhibitor (DNRI), classifying it as a wake-promoting agent. This means it works by targeting specific brain pathways to sustain wakefulness. Its mechanism of action is described as different from that of traditional central nervous system stimulants.

Q: How quickly is Sunosi expected to start working?

Information from clinical trials reported measurements of objective wakefulness that were recorded as early as one hour after the medicine was taken. The drug is intended to help improve wakefulness and reduce excessive daytime sleepiness throughout the day.

Q: What happens if I miss a dose of Sunosi?

If a dose is missed, regulatory administration instructions advise skipping the dose if the time until your planned bedtime is less than nine hours. This precaution is advised to avoid the potential for the medicine to interfere with nighttime sleep.

Q: Is Sunosi considered habit-forming or addictive?

Sunosi is federally classified as a Schedule IV controlled substance. This classification is used for medicines that have a recognized potential for abuse and physical dependence. Official guidance includes recommendations for health professionals to evaluate patients for any history of drug abuse.

Q: Can women take Sunosi while pregnant or breastfeeding?

Regulatory documents state that the medicine is not recommended during pregnancy or while breastfeeding. This is because it is unknown if Sunosi will harm an unborn baby and because the medicine is known to be excreted in human milk, meaning it can pass to the infant.

Q: Is Sunosi used for conditions other than narcolepsy or OSA?

The official indication for this medicine is exclusively for the treatment of excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnea (OSA). The medicine is not officially indicated for use in conditions other than narcolepsy or OSA.

Q: Will I feel 'high' or euphoric after taking Sunosi?

The regulatory labeling includes warnings related to the medicine's potential for abuse. Official warnings also advise monitoring for psychiatric symptoms such as increased anxiety, restlessness, and irritability, which have been reported in some individuals.

Q: What are the differences between Sunosi and modafinil?

One difference noted in regulatory assessments relates to interactions with other medicines. Official assessments found that Sunosi is not expected to have a clinically significant interaction with hormonal contraceptives (birth control pills).

Q: Are there any specific foods or drinks to avoid while taking Sunosi?

Pharmacokinetic studies showed that consuming a high-fat, high-calorie meal does not change the amount of medicine absorbed by the body. Regulatory labeling does not list specific food or drink restrictions.

Q: Is it safe to drink alcohol in moderation while on Sunosi?

While the regulatory label does not list a specific interaction with alcohol, general patient safety guidance advises caution with substances that can contribute to sleepiness. Alcohol may potentially contribute to sleepiness, which could oppose the intended wake-promoting effects.

Q: Can Sunosi make insomnia or trouble sleeping worse?

Insomnia, meaning difficulty sleeping or trouble staying asleep, is described in regulatory documents as a common adverse reaction associated with the medicine. Patients are advised in regulatory information to inform a health professional if they develop problems sleeping.

Q: Is Sunosi a cure for narcolepsy or sleep apnea?

The medicine is officially indicated for improving wakefulness and treating the symptom of excessive daytime sleepiness (EDS). Regulatory information makes clear it is not indicated as a treatment for the underlying airway obstruction that causes OSA.

Q: Will I develop a tolerance to Sunosi over time?

Long-term open-label extension studies, which followed patients for up to 52 weeks, described sustained measurements in wakefulness and sleepiness scales. This research did not suggest a clinically relevant loss of effect over the studied period.

Q: Is Sunosi safe to use long-term?

Long-term safety was evaluated in open-label extension studies for up to 52 weeks, during which patients continued to be monitored. The long-term use of any medicine involves ongoing monitoring by a health professional.

Q: What happens when people stop taking Sunosi?

Safety data collected during clinical evaluation did not suggest the occurrence of a withdrawal syndrome upon abrupt discontinuation of the medicine. This aligns with its classification as a controlled substance with a low potential for physical dependence.

Q: Does Sunosi change the way I sleep at night?

Clinical studies described that the medicine did not interfere with or change the characteristics of nighttime sleep when administered according to regulatory guidance. Official administration guidance states it should be taken at least nine hours before planned bedtime to avoid disrupting sleep.

Q: Does Sunosi interact with birth control pills?

Official assessments found that Sunosi is not expected to have a clinically significant interaction with hormonal contraceptives (birth control pills). This is based on regulatory pharmacokinetic assessments.

Q: Can Sunosi be taken with herbal supplements?

While specific interactions with herbal supplements are not listed in the official prescribing information, patient safety guidance includes a recommendation to disclose all products, including herbal supplements, vitamins, and over-the-counter medicines, to a health professional before taking Sunosi.

Q: What kind of patient monitoring is necessary while taking Sunosi?

The regulatory label advises that a health professional assess and control blood pressure before starting the medicine and monitor blood pressure and heart rate regularly during treatment. Monitoring for the appearance of psychiatric symptoms is also advised.

How to Store and Dispose of Sunosi (Solriamfetol)

Sunosi must be stored at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F). Brief temperature excursions are permitted between 15 C and 30 C (59 F and 86 F).

Security and Child Safety

As a federally controlled substance (CIV), the medication must be secured in a safe place or a locked cabinet to prevent misuse. Sunosi must be kept out of the reach of children.

Handling and Stability

Containers must be kept tightly closed to protect the tablets from moisture. If dispensed in a bottle, the tablets should be used or disposed of within four months of the first opening.

Disposal Instructions

Dispose of unused or expired Sunosi primarily through a medication take-back program. If a take-back option is unavailable, the official alternative procedure is to mix the tablets with an undesirable substance, such as coffee grounds, place the mixture in a sealed bag, and discard it in the household trash.